Europe is facing major economic challenges that require an ambitious economic policy for the 21st century. The EU has set out its vision for Europe's social market economy in the Europe 2020 strategy, which aims at confronting our structural weaknesses through progress in three mutually reinforcing priorities : • smart growth, based on knowledge and innovation, • sustainable growth, promoting a more resource efficient, greener and competitive economy, • inclusive growth, fostering a high employment economy delivering economic, social and territorial cohesion. MANUNET III, as a continuation of MANUNET II, is aligned with the European priorities and pretends to create a smart sustainable growth in the European manufacturing sector by coordinating the research and innovation efforts in the field of advanced manufacturing with a special focus in the key areas of new production processes, adaptive manufacturing systems and technologies for the factory of the future. The project will also reinforce the territorial cohesion through an extended collaboration network. The consortium pretends to respond to the actual economic crisis by promoting the transnational research, innovation and entrepreneurship in the industrial sector, especially in the SMEs, which are the backbone of Europe's economy. Through this strategic and integrated approach to innovation in advanced manufacturing, MANUNET III pretends to maximise European, national and regional research and innovation potential.

The ERA-Net “Cofund on BioTechnologies” (ERA CoBioTech) aims to better use synergies between current mechanisms of biotechnology research funding in Europe, to highlight the benefits of a bio-based economy for society, and to thus maintain and strengthen Europe’s global lead in modern biotechnology. The co-funded call will focus on application-oriented research in: a) Synthetic biology approaches to design and construct new biological parts, devices and systems b) Systems biology approaches to metabolic engineering and optimisation of biological processes c) Identification and use of the metabolic potentials of genomic data d) Chemical and biotechnological approaches to transform bio-based molecules into molecules with high added value. Bundling three predecessor ERA-Nets in the area of biotechnology, ERA CoBioTech significantly increases public funding (call volume ~ 30 Mio €), intensifies collaboration across relevant sectors and countries, and thus - advances RD&I in industrial biotechnology - establishes systems and synthetic biology as technology drivers in applied biotechnology, and - enhances the potential for exploitation through active industry involvement. Necessary steps and measures to achieve these goals will be encompassed in a joint Strategic Agenda. With a “European Biotechnology Hub”, ERA CoBioTech realises an entirely new concept, reaching out to key actors and stakeholders from multiple biotechnology-related areas in order to align different European strategic instruments with the goals of the KET biotechnology programme under Horizon 2020 and to increase public awareness of biotechnology for industrial uses. ERA CoBioTech will implement additional funding activities without EC co-funding, which will advance RD&I in industrial biotechnology in line with the Strategic Agenda and the outcomes of the "European Biotechnology Hub." ERA CoBioTech thus provides biotechnology stakeholders with tailor-made support regarding information, communication, networking and funding.